EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Individualized pharmacogenomics for depressive episodes: A narrative review

Michel Haddad, Luiz Henrique Junqueira Dieckmann, Giovana Regina Weber Hoss, Jair de Jesus Mari, Allan H Young, Mario F Juruena

Journal of Affective Disorders · 2026-12 · 414 · 122261

DOI: 10.1016/j.jad.2026.122261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Michel Haddad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Brazilian Clinical Research Institute, São Paulo, Brazil; Department of Psychiatry, Universidade Federal de São Paulo, São …. Hauptthemen laut MEDLINE: Major Depressive Disorder, Pharmacogenetics, Precision Medicine, Antidepressive Agents. Die Arbeit nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) and bipolar disorder (BD) are highly prevalent psychiatric conditions, both characterized by depressive episodes and associated with substantial disability, marked clinical heterogeneity, and variable responses to pharmacological treatment. Despite the widespread use of antidepressants and antipsychotics, a significant proportion of patients experience delayed therapeutic response, adverse drug reactions, or treatment resistance, due to interindividual biological variability. In this context, pharmacogenomics has emerged as a key strategy to address this challenge by integrating genetic variability with pharmacokinetic and pharmacodynamic mechanisms to inform personalized treatment decisions. This narrative review aims to: (i) summarize key pharmacogenes and genetic variants implicated in the pharmacological treatment of MDD; (ii) differentiate genes with established clinical actionability from those requiring further evidence; and (iii) evaluate their current and future roles in precision psychiatry. Evidence was synthesized from curated pharmacogenomic guideline resources, including the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Pharmacogenomics Knowledge Base (PharmGKB), and the Dutch Pharmacogenetics Working Group (DPWG). Robust and replicated evidence supports the clinical employ of the pharmacokinetic genes CYP2D6 and CYP2C19, for which genotype-informed prescribing recommendations are available and have demonstrated benefits in optimizing drug exposure, reducing adverse effects, and improving treatment outcomes, particularly for selective serotonin reuptake inhibitors (SSRIs). CYP3A4 and CYP1A2 contribute substantially to the metabolism of many psychotropic drugs and influence dosing through both genetic and environmental modifiers (e.g., enzyme inducers/inhibitors and smoking), although formal guideline-level recommendations remain limited for a small subset of substrates. In contrast, pharmacodynamic and regulatory genes, including COMT, FKBP5, HTR2A, SLC6A4, and MTHFR, represent promising avenues for future clinical implementation. Polygenic risk scores for antidepressant response (PRS-AD) capture the highly polygenic architecture of treatment outcomes but, at present, lack the predictive performance required for routine clinical use, particularly across non-European ancestries. Randomised trials and meta-analyses (GUIDED, PRIME Care, IGNITE-network and others) provide moderate evidence that pharmacogenomic-guided prescribing modestly improves remission, response, and side-effect burden; however, the magnitude and durability of benefit remain under active debate. Pharmacogenomic testing therefore represents a clinically informative - though not curative - adjunct to psychiatric care; its full potential will be achieved by combining routine guideline-based testing of validated pharmacogenes with ongoing translational research on emerging candidates and polygenic models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderPharmacogeneticsPrecision MedicineAntidepressive AgentsBipolar DisorderHumansTreatment Effect Heterogeneity

Stichwörter der Autor:innen

CYP2C19CYP2D6Major depressive disorderPharmacogenomicsPrecision psychiatry

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Brazilian Clinical Research Institute, São Paulo, Brazil; Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: michel@fluturepsiquiatria.com.br.
  • Department of Psychiatry, Brazilian Clinical Research Institute, São Paulo, Brazil; Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Universidade Federal do Rio Grande do Sul, Department of Genetics and Molecular Biology, Porto Alegre, Brazil.
  • Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; South London and Maudsley NHS Foundation Trust (SLaM), UK.

Zitieren

APA

Haddad, M., Dieckmann, L. H. J., Hoss, G. R. W., de Jesus Mari, J., Young, A. H., & Juruena, M. F. (2026). Individualized pharmacogenomics for depressive episodes: A narrative review. Journal of Affective Disorders, 414, 122261. https://doi.org/10.1016/j.jad.2026.122261

Vancouver

Haddad M, Dieckmann LHJ, Hoss GRW, de Jesus Mari J, Young AH, Juruena MF. Individualized pharmacogenomics for depressive episodes: A narrative review. Journal of Affective Disorders. 2026;414:122261. doi:10.1016/j.jad.2026.122261

BibTeX
@article{Haddad2026,
  author = {Haddad, Michel and Dieckmann, Luiz Henrique Junqueira and Hoss, Giovana Regina Weber and de Jesus Mari, Jair and Young, Allan H and Juruena, Mario F},
  title = {Individualized pharmacogenomics for depressive episodes: A narrative review},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {414},
  pages = {122261},
  doi = {10.1016/j.jad.2026.122261}
}
Kostenlos starten →